US Edition
Eyerising International addresses 'limitations' of red light study suggesting reduced cone density
Summary by Insight
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Eyerising International addresses 'limitations' of red light study suggesting reduced cone density
The Eyerising Myopia Management Device was approved in Australia in 2023. Image: Eyerising International. The inventor of the Eyerising International repeated low-level red light (RLRL) therapy for myopia, Professor Mingguang He, has outlined “notable design flaws” in a study suggesting reduced cone density in children who received the therapy and has provided a glimpse into upcoming studies he expects to show opposite findings. Prof He, the com…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
